Optimization of Combination Strategies: Explore novel therapeutic synergies through dual-targeting approaches, small-molecule TKIs (e.g., pyrotinib), HER2/EGFR bispecific antibodies (Targeting bypass resistance pathways), Immunotherapy augmentation through, enhancing systemic anti-tumor immunity beyond PD-1 blockade, CTLA-4 inhibitors and oncolytic viruses. This evidence concerns the gene ERBB2 and neoplasm.